3 lectures · 104 items
Stroke Insights – Connecting science and lived experience
Heart failure is common in people with atrial fibrillation detected during screening
Stroke identified as the second leading cause of death from cardiovascular disease and a major contributor of acquired long-term disability
PCSK9 Inhibitor Prevents First Heart Attack or Stroke in High-Risk PatientsSlides | Update on stroke prevention in atrial fibrillationUpdate on stroke prevention in atrial fibrillationLower extremity artery disease: a neglected major CV disease
Погоджена настанова EPCCS щодо профілактики інсульту при фібриляції передсердь в системі надання первинної медичної допомоги
EPCCS consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary careA Scientific Statement From the American Heart Association.
The American Heart Association highlights the substantial clinical and public health burden of antithrombotic undertreatment in patients with atrial fibrillation, venous thromboembolism, or…
Persistent Value and the Contemporary Role of Vitamin K Antagonism.
This narrative review outlines the contemporary indications for vitamin K antagonists (VKAs) in cardiovascular practice. While DOACs have largely replaced warfarin for atrial fibrillation, VKAs…
An updated meta-analysis of six randomized trials (7,028 patients) comparing percutaneous left atrial appendage closure (LAAC) with oral anticoagulation in nonvalvular atrial fibrillation found…
Competing Adverse Events in a Nationwide Cohort.
In a nationwide Finnish cohort of 1,502 patients with atrial fibrillation and prior intracranial bleeding, the 1-year risk of ischemic stroke fell from 4.1% with no anticoagulation to 0.7% with DOACs…
This Circulation review examines how a broad spectrum of anticancer therapies, including chemotherapy, hormonal agents, and targeted inhibitors, significantly increases the risk of venous and…
This Circulation review addresses the growing population of Kawasaki disease survivors at risk for acute coronary syndrome, highlighting how KD-specific coronary pathology and thrombosis risk diverge…
A COMBINE-AF Analysis.
A pooled analysis of five pivotal randomized trials (COMBINE-AF; n=73,737) demonstrates that extracranial bleeding occurs in 26% of patients with atrial fibrillation on oral anticoagulants over a…
the safety and efficacy of oral anticoagulants in atrial fibrillation patients with prior intracranial haemorrhage: a systematic review and meta-analysis.
A systematic review and meta-analysis evaluated direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with atrial fibrillation and a history of intracranial haemorrhage…
milvexian prevents no events after an acute coronary syndrome and does not bleed less, a blow to the factor XI hypothesis in ACS
The full results of the trial stopped for futility in November 2025: 14,194 patients within 7 days of an ACS with at least two risk factors, milvexian 25 mg twice daily or placebo on top of…
the hypothesis, the promise and the LIBREXIA ACS lesson
Factor XI inhibition promises antithrombotic effect without the bleeding cost, but the field keeps hitting reality: after asundexian, the 14,000-patient LIBREXIA ACS trial of milvexian was halted for…
A recent narrative review synthesizes evidence on antithrombotic management in patients with stable chronic coronary syndrome (CCS) and atrial fibrillation (AF). Trials including AFIRE, EPIC-CAD…
Care pathways in atrial fibrillation (AF) are poorly characterised and may influence guideline-concordant treatment. In the Optum database (37,370 patients with incident AF, 2015–2023), 20.6% had a…
